An angel investor sells half of her 18% stake in a biotech startup for $90,000 after the company achieves a $450,000 exit valuation. What was her initial investment if her remaining stake is now worth $45,000?

Mon, 04 May 2026 09:57:22 +0000

**Why Biomedical Breakthroughs Are Fueling Interest in Early-Stage Investments – The Story Behind a $90,000 Trade** When bits of science meet high-stakes finance, investor stories like those unfolding in biotech often capture attention—especially as early-stage ventures turn headlines. Recently, an angel investor made news by selling half of her 18% ownership in a deep-tech biotech startup for $90,000, following the company’s successful $450,000 exit via acquisition. The investor now holds a $45,000 stake, raising the timeless question: What was her original investment? This shift reflects a growing trend among risk-tolerant investors navigating high-growth sectors where innovation meets tangible economic returns. As venture capital becomes increasingly laser-focused on life science breakthroughs, transactions like this demonstrate how partial exits offer crucial liquidity while preserving long-term upside. ---